Verastem, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing medicines for cancer. Its marketed product is AVMAPKI FAKZYNJA CO-PACK (avutometinib capsules; defactinib tablets). Its pipeline includes avutometinib (RAF/MEK inhibitor), defactinib (FAK inhibitor), and VS-7375 (a selective oral KRAS G12D dual ON/OFF inhibitor). The company conducts clinical trials including RAMP 201, RAMP 201J, RAMP 205, RAMP 301, and VS-7375 trials.
Q2 FY2026 — expected 2026-09-10
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-04 | 2025-12-31 | 0001104659-26-023444 | EDGAR | 103K words |
| 2025-03-20 | 2024-12-31 | 0001558370-25-003372 | EDGAR | — |
| 2024-03-14 | 2023-12-31 | 0001558370-24-003250 | EDGAR | — |
| 2023-03-14 | 2022-12-31 | 0001558370-23-003738 | EDGAR | — |
| 2022-03-28 | 2021-12-31 | 0001558370-22-004498 | EDGAR | — |
| 2021-03-18 | 2020-12-31 | 0001558370-21-003211 | EDGAR | — |
| 2020-03-11 | 2019-12-31 | 0001558370-20-002421 | EDGAR | — |
| 2019-03-12 | 2018-12-31 | 0001558370-19-001852 | EDGAR | — |
| 2018-03-13 | 2017-12-31 | 0001558370-18-001953 | EDGAR | — |
| 2017-03-23 | 2016-12-31 | 0001558370-17-002065 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-04 | 2025-09-30 | 0001104659-25-106279 | EDGAR | 38K words |
| 2025-08-07 | 2025-06-30 | 0001558370-25-010757 | EDGAR | — |
| 2025-05-13 | 2025-03-31 | 0001558370-25-007570 | EDGAR | — |
| 2024-11-06 | 2024-09-30 | 0001558370-24-014640 | EDGAR | — |
| 2024-08-08 | 2024-06-30 | 0001558370-24-011599 | EDGAR | — |
| 2024-05-09 | 2024-03-31 | 0001558370-24-007607 | EDGAR | — |
| 2023-11-08 | 2023-09-30 | 0001558370-23-018281 | EDGAR | — |
| 2023-08-08 | 2023-06-30 | 0001558370-23-013946 | EDGAR | — |
| 2023-05-09 | 2023-03-31 | 0001558370-23-008839 | EDGAR | — |
| 2022-11-03 | 2022-09-30 | 0001558370-22-016278 | EDGAR | — |
| 2022-08-08 | 2022-06-30 | 0001558370-22-012638 | EDGAR | — |
| 2022-05-09 | 2022-03-31 | 0001558370-22-007848 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-04 | 0001104659-26-023462 | EDGAR | 6K words |
| 2026-02-04 | 0001104659-26-010036 | EDGAR | — |
| 2026-01-08 | 0001104659-26-002135 | EDGAR | — |
| 2025-12-31 | 0001104659-25-125309 | EDGAR | — |
| 2025-12-19 | 0001104659-25-123295 | EDGAR | — |
| 2025-11-17 | 0001104659-25-112946 | EDGAR | — |
| 2025-11-04 | 0001104659-25-105923 | EDGAR | — |
| 2025-10-23 | 0001104659-25-101817 | EDGAR | — |
| 2025-10-20 | 0001104659-25-100537 | EDGAR | — |
| 2025-09-08 | 0001104659-25-088021 | EDGAR | — |
247 total filings indexed. 215 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001526119 |
| Ticker | VSTM |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | MA |
| Website | https://www.verastem.com |
| Listed | 2012-01-27 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report